Growth momentum Glaukos posted strong Q2 2026 revenue growth with net sales around $185–186 million, signaling expanding market adoption of ophthalmic therapies and a potential opportunity to upsell additional dropless platform technologies and related care pathways.

Global expansion The company holds exclusive development and commercialization rights for PRESERFLO MicroShunt in multiple major markets (US, Australia, New Zealand, Canada, Brazil, Mexico), indicating a need for regional partner ecosystems, training, and aftermarket support to accelerate surgeon adoption.

Dropless pipeline Glaukos emphasizes a robust dropless platform pipeline, presenting a cross-sell opportunity to clinics and health systems seeking streamlined postoperative regimens, reduced patient visits, and improved outcomes across glaucoma, corneal, and retinal care.

Clinical adoption Real-world evidence and expanding surgeon adoption of PRESERFLO in existing markets suggest opportunities to provide clinical education, KOL partnerships, and data-sharing initiatives to accelerate market penetration and expand account coverage.

Strategic partnerships With ongoing development in iLink cross-linking therapy and collaboration under licensing with Santen, there is potential to pursue co-marketing, training programs, and bundled solutions that align with ophthalmology practices seeking integrated eye-care innovations.